Bharat Biotech claims 77.8% efficacy for Covaxin in Phase 3 trials

Data from the Phase 3 trials of Covaxin show that the vaccine is 77.8% effective against Covid-19, Bharat Biotech sources have claimed. The Subject Expert Committee (SEC) has reviewed Bharat Biotech’s data, but no approval has been given yet.

The expert panel met on Tuesday afternoon to review the Covaxin trial results. Bharat Biotech made a presentation in which the data was presented to the panel, showing 77.8% efficacy of Covaxin.

The SEC will now send the data to the Drugs Controller General of India (DCGI) for review. The SEC is now looking at the data.